فهرست مطالب
Archives of Clinical Infectious Diseases
Volume:16 Issue: 5, Oct 2021
- تاریخ انتشار: 1400/12/12
- تعداد عناوین: 11
-
-
Page 2Background
Infection caused by SARS-CoV-2 can lead to significant procoagulant events, sometimes involving life-threatening pulmonary thromboembolism (PE). Additional conditions complicating the diagnosis are the presence of risk factors for PE in almost all patients with COVID-19 and the overlap of clinical presentation between PE and COVID-19.
ObjectivesWe conducted a single-center study at the Heart and Brain Hospital, Pleven, from December 2020 to February 2021. It included 27 consecutively hospitalized patients with recent pneumonia caused by COVID-19 and clinical presentations corresponding to PE.
MethodsThe cohort was divided into two groups with and without a definitive diagnosis of PE, proven by CT pulmoangiography. The aim was to find the indicators predicting the presence of PE in patients with acute or post-acute COVID-19 conditions.
ResultsOur results showed that some ECG criteria, including S-wave over 1.5 mm in leads I and aVL (P = 0.007), Q-wave in leads III and aVF (P = 0.020), and D-dimer as a quantitative variable (P = 0.025), were independent predictors of PE. The RV/LV diameter ratios ≥ 1.0 and right ventricular dysfunction showed a sensitivity (Se) of 62.5%, specificity (Sp) of 100%, positive predictive value (PPV) of 100%, and negative predictive value (NPV) of 86.4% to verify the PE diagnosis. Besides, the D-dimer cutoff value of 1,032 ng/mL had an optimal Se of 87.5%, Sp of 57.9%, PPV of 46.7%, and NPV of 91.7% for PE diagnosis (P = 0.021).
ConclusionsAgainst the background of acute and post-acute COVID-19 conditions, ECG and EchoCG criteria remain the PE predictors. We suggest that a higher D-dimer cutoff value be applied in COVID-19 and post-COVID-19 patients to confirm/dismiss PE diagnosis.
Keywords: Infection, COVID-19, Pulmonary Thromboembolism, D-dimer -
Page 3Background
Evidence suggests that COVID-19 patients are subject to significant risks of thromboembolic complications.
ObjectivesWe aimed to evaluate coagulation disorders in COVID-19 patients and determine their relationship with the disease outcome.
MethodsThis cross-sectional study was conducted on 106 COVID-19 patients hospitalized in Imam Khomeini Hospital, Ardabil, Iran. After the preliminary completion of the information forms, 3 cc of intravenous blood sample was taken from each patient to test for INR, PT, CBC, and D-dimer. Then, the patients were monitored, and clinical data were statistically analyzed using SPSS software, version 24.
ResultsOf 106 COVID-19 patients, 69 were discharged from the hospital, while 37 cases died. The mean age of the patients was 58.99 ± 15.94 years, and 56.6% were males. Significant differences were found between the surviving and deceased patients in D-dimer, LDH, PT, and INR levels (P < 0.05). Based on logistic regression analysis, only D-dimer was a significant predictor of mortality such that each unit increase in the D-dimer level increased the mortality risk by 0.99%.
ConclusionsD-dimer has a higher sensitivity than other coagulation markers in terms of intensity. As bleeding is not as common as thrombotic events, anticoagulant therapy is recommended.
Keywords: COVID-19, Coagulation Disorders, Outcome, Thrombocytopenia -
Page 4Context
Cancer patients aremore susceptible to novel coronavirus infection due to their immune system deficiency and anticancer treatments. During the COVID-19 outbreak, cancer patients have faced many challenges. The present study aimed to review the literature on cancer patients’ challenges during the COVID-19 pandemic to offer an approach to decision-making in management and policy-making.
Evidence AcquisitionIn this review study, national and international databases were searched. Inclusion Criteria were the risk of COVID-19 in cancer patients, medical services, surgery, and cancer screening during the COVID-19 pandemic, cancer patients’ challenges during the COVID-19 pandemic, and management and policy-making in this pandemic.
ResultsCancer patients’ challenges during the COVID 19 pandemic were classified as follows: (1) risk of COVID-19 for cancer patients; (2) access to medical services and screening during the COVID-19 pandemic; and (3) psychological disorders during the COVID-19 pandemic. Studies have revealed that individuals with cancer experience a higher risk of the COVID-19 infection and mortality compared to healthy individuals. Most oncology clinics postpone unnecessary appointments; however, patients with invasive cancer are treated with no delay. Proper management, disease control, and attention to mental health care can prevent psychological disorders.
ConclusionsManaging cancer patients’ challenges during the SARS-CoV-2 is of paramount importance. Cancer clinics need to develop new care and follow-up protocols. Moreover, policy-makers should provide appropriate policies to address the challenges of this disease in the future.
Keywords: nCoV-2019, COVID-19, SARS-cov19, Cancer, Malignancy, Policy-Making, Management -
Page 5
On December 29, 2019, an epidemic of an infectious disease caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was declared in Wuhan, China. The first case of COVID-19 in Iran (Qom Province) was reported in February 2020, and within a short period, the number of infected cases increased rapidly around the country. Evidence suggests that the levels of pro-inflammatory cytokines are high in critically ill patients, and there is a correlation between the high level of cytokines and the pathogenesis of COVID19; consequently, COVID-19 may have complications, such as acute respiratory distress syndrome (ARDS) and even death. These inflammatory factors can lead to a cytokine storm, while counteracting this storm seems to be an effective therapeutic approach. In this case series, we reported two critically ill patients with COVID-19, undergoing plasmapheresis with convalescent plasma, corticosteroid therapy, and interferon administration.
Keywords: Plasmapheresis with Convalescent Plasma, Rescue Therapy, COVID-19 Patients -
Page 6Background
With the emergence and spread of coronavirus disease 2019 (COVID-19) globally, health care systems have faced the biggest challenge in recent decades.
ObjectivesThe present study aimed to identify risk factors associated with oropharyngeal candidiasis (OPC) in COVID-19 patients.
MethodsThe total number of confirmed COVID-19 patients was 218 (105 cases with OPC and 113 controls without OPC). The questionnaire used in this study consisted of demographic data, treatment strategy, clinical and laboratory data, and underlying diseases collected from the onset of clinical OPC until the end of hospitalization.
ResultsPseudomembranous candidiasis (77/105, 73.3%) was the most prevalent form of OPC in case patients. The majority of the cases (58.1%) and controls (58.4%) were males. Increasing age (P = 0.03) and hospitalization length (P = 0.016) were significantly associated with OPC in COVID-19 patients. Diabetes (P = 0.003), solid tumor (P = 0.019), and hypertension (P = 0.000) were the most common underlying conditions. The use of dentures (P = 0.003) and poor oral hygiene (P = 0.000) were related to OPC in the case group. Therapy with chloroquine (P = 0.012), IVIG (P = 0.001), diuretics (P = 0.000), and corticosteroid pulse therapy (P = 0.000) were significantly associated with developing OPC in case patients.
ConclusionsOld age, hospitalization length, poor oral hygiene, corticosteroids use, diabetes, solid tumor, and hypertension may predispose COVID-19 patients to develop OPC
Keywords: Oropharyngeal Candidiasis, COVID-19, Risk Factors -
Page 7Context
COVID-19 severe manifestations must be detected as soon as possible. One of the essential poor characteristics is the involvement of coagulopathy. Simple coagulation parameters, including prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and platelet, are widely accessible in many health centers.
ObjectivesThis meta-analysis aimed to determine the association between simple coagulation profiles and COVID-19 in-hospital mortality.
MethodWe systematically searched five databases for studies measuring simple coagulation parameters in COVID-19 on admission. The random-effects and inverse-variance weighting were used in the study, which used a standardized-mean difference of coagulation profile values. The odds ratios were computed using the Mantel-Haenszel formula for dichotomous variables.
ResultsThis meta-analysis comprised a total of 30 studies (9,175 patients). In our meta-analysis, we found that non-survivors had a lower platelet count [SMD = -0.56 (95% CI: -0.79 to -0.33), P < 0.01; OR = 3.00 (95% CI: 1.66 to 5.41), P < 0.01], prolonged PT [SMD = 1.22 (95%CI: 0.71 to 1.72), P < 0.01; OR = 1.86 (95%CI: 1.43 to 2.43), P < 0.01], prolonged aPTT [SMD = 0.24 (95%CI: -0.04 to 0.52), P = 0.99], and increased INR [SMD = 2.21 (95%CI: 0.10 to 4.31), P = 0.04] than survivors.
ConclusionsIn COVID-19 patients, abnormal simple coagulation parameters on admission, such as platelet, PT, and INR, were associated with mortality outcomes.
Keywords: COVID-19, Coagulopathy, Coagulation Profile, Platelet, Mortality -
Page 9Background
Returning symptomatic patients with a history of recovered COVID-19 with a new positive SARS CoV-2 PCR test after several weeks to months of a negative PCR result is challenging during the COVID-19 pandemic.
ObjectivesWe aimed to determine such Iranian patients’ clinical and laboratory characteristics and discuss possible reasons.
MethodsWe retrospectively investigated SARS CoV-2 PCR tests in three referral hospitals. All patients who had the following criteria were included in the study: two SARS CoV-2 PCR-positive tests three months apart, no symptoms, a negative PCR test between the two positive tests, and access to the patient and medical information. Then, we retrospectively recorded the clinical and laboratory characteristics of the eligible patients. We also compared the clinical and laboratory features in the first and second episodes.
ResultsAmong 1,899 patients, 37 cases were eligible in the study based on our criteria. The majority of patients were males and nurses. The mean age was 37.54 ± 15.16 years. Weakness, myalgia, and fever were the most frequent clinical symptoms in both episodes. The mean interval between discharge and second presentation was 117 ± 61.42 days. The clinical, radiological, and laboratory characteristics were not significantly different between the two episodes, except for significantly more dexamethasone use in the second episode (P = 0.03).
ConclusionsWe could not cultivate the virus and perform the phylogenic sequencing of SARS-CoV-2; however, the prolonged interval between the two episodes suggests probable reinfection in our cases. Finally, this clinical phenomenon may be more common in HCW without a significant consequence; however, most cases were HCW who had more compatibility with our criteria due to the availability of their medical information
Keywords: COVID-19, Reactivation, Reinfection, Relapse -
Page 10
-
Page 11Background
During surgical treatment of hydatidosis, spillage of live protoscolices is a major cause of secondary infection. Although some studies have suggested scolicidal agents for preventing secondary infection, no safe scolicidal agents have been introduced so far.
ObjectivesThis study aimed to determine the minimum scolicidal concentration of chlorhexidine gluconate (Chx-Glu) with 100% fatality and evaluate its toxicity on the liver, biliary tract, and peritoneum.
MethodsThe minimum scolicidal concentration of Chx-Glu after 5 and 10 minutes in vitro (0.08% after 5 and 0.06% after 10 min) was determined in this study. Then, the experiments were conducted on male New Zealand rabbits (n=30), which were divided into two groups. Under the guidance of ultrasonography, intraperitoneal, hepatic parenchyma, and gallbladder injection of Chx-Glu 0.08% and 0.06% were performed in groups A and B, respectively. Liver enzymes were checked before and 48 hours after Chx-Glu injection, and histological assessments were performed 45 days later.
ResultsThere was no significant difference in the plasma levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and bilirubin before and after the injection (P > 0.05) and after that between the two groups (P > 0.05). There was no major tissue destruction based on histological study except the nonsignificant histologically focal gallbladder mucosal atrophy in two rabbits in group A and one in group B.
ConclusionsOur study suggests that Chx-Glu at 0.06 - 0.08 % is a safe scolicidal agent without major tissue toxicity in the animal models that can be used to prevent secondary infection during hydatid cyst surgery.
Keywords: Echinococcosis, Chlorhexidine Gluconate, Ultrasonography, Hydatid Cyst